Knight Therapeutics (TSE:GUD) Trading Down 0.3% – Time to Sell?

Knight Therapeutics Inc. (TSE:GUD) dropped 0.3% on Monday . The company traded as low as C$5.72 and last traded at C$5.74. Approximately 37,679 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 66,094 shares. The stock had previously closed at C$5.76.

Wall Street Analysts Forecast Growth

GUD has been the subject of a number of analyst reports. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Knight Therapeutics Stock Performance

The stock’s 50 day moving average price is C$5.77 and its 200 day moving average price is C$5.74. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. The firm has a market cap of C$580.95 million, a PE ratio of -28.70, a P/E/G ratio of -1,013.50 and a beta of 0.48.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings results on Thursday, August 8th. The company reported C($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.03 by C($0.05). Knight Therapeutics had a negative return on equity of 2.70% and a negative net margin of 6.28%. The firm had revenue of C$95.57 million for the quarter, compared to analysts’ expectations of C$89.83 million. As a group, equities analysts forecast that Knight Therapeutics Inc. will post 0.1101871 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Knight Therapeutics news, insider Sime Armoyan sold 300,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. In other Knight Therapeutics news, insider Sime Armoyan sold 300,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Also, Senior Officer Amal Khouri sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of C$5.75, for a total transaction of C$28,750.00. Insiders have sold 310,500 shares of company stock valued at $1,899,544 in the last quarter. Company insiders own 45.60% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.